For example, the predicted moderate overexpression of BCL2 in accelerated and blast phase suggests that drugs like venetoclax could potentially be an option for CML patients in advanced phases [62,63]. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.